Vaxart, Inc. VXRT

VXRT Company Overview

Vaxart, Inc. is a U.S.-based biotechnology company focused on the development of oral recombinant vaccines delivered in tablet form rather than by injection. The company operates within the biotechnology and vaccine development industries, with a strategic emphasis on mucosal immunology and oral delivery technologies intended to stimulate immune responses at the site of viral entry. Its pipeline has included vaccine candidates targeting COVID-19, norovirus, influenza, and other infectious diseases, with most programs remaining in clinical or preclinical development stages based on publicly available filings and corporate disclosures.

The company’s primary revenue sources historically have consisted of collaboration agreements, government-supported research funding, and licensing arrangements rather than commercialized product sales. Vaxart’s positioning is tied to its proprietary oral vaccine platform, which is designed to simplify vaccine distribution and administration by reducing dependence on needles and certain cold-chain logistics. Founded in 2004, the company evolved through a series of mergers, restructurings, and public market financing activities, later becoming publicly traded on Nasdaq under the ticker VXRT. Public filings indicate the company has continued to prioritize infectious disease vaccine development and platform validation through clinical studies and external partnerships.